CATX Perspective Therapeutics Inc
Price (delayed)
$2.45
Market cap
$181.43M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.23
Enterprise value
$123.91M
Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.
Highlights
The company's quick ratio rose by 31% QoQ
Perspective Therapeutics's EPS has increased by 29% YoY and by 18% from the previous quarter
The debt has surged by 59% year-on-year but it has declined by 4.8% since the previous quarter
The net income has plunged by 70% YoY and by 24% from the previous quarter
CATX's equity is down by 12% since the previous quarter
Key stats
What are the main financial stats of CATX
Market
Valuations
Earnings
Shares outstanding
74.05M
Market cap
$181.43M
Enterprise value
$123.91M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.57
Price to sales (P/S)
108.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
85.22
Revenue
$1.45M
Gross profit
$1.45M
Operating income
-$90.89M
Net income
-$79.28M
EBIT
-$81.33M
EBITDA
-$79.02M
Free cash flow
-$72.37M
Per share
Balance sheet
Liquidity
EPS
-$1.23
EPS diluted
-$1.23
Free cash flow per share
-$1.12
Book value per share
$4.3
Revenue per share
$0.02
TBVPS
$4.52
Total assets
$341.1M
Total liabilities
$50.43M
Debt
$4.06M
Equity
$290.67M
Working capital
$212.93M
Debt to equity
0.01
Current ratio
12.68
Quick ratio
12.45
Net debt/EBITDA
0.73
Margins
Efficiency
Dividend
EBITDA margin
-5,434.8%
Gross margin
100%
Net margin
-5,452.5%
Operating margin
-6,250.8%
Return on assets
-22.7%
Return on equity
-26.6%
Return on invested capital
-84.4%
Return on capital employed
-25.2%
Return on sales
-5,593.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CATX stock price
How has the Perspective Therapeutics stock price performed over time
Intraday
1.66%
1 week
5.15%
1 month
11.36%
1 year
-85.42%
YTD
-23.2%
QTD
15.02%
Financial performance
How have Perspective Therapeutics's revenue and profit performed over time
Revenue
$1.45M
Gross profit
$1.45M
Operating income
-$90.89M
Net income
-$79.28M
Gross margin
100%
Net margin
-5,452.5%
The operating income has plunged by 122% YoY and by 58% from the previous quarter
CATX's operating margin has dropped by 119% year-on-year and by 69% since the previous quarter
The net income has plunged by 70% YoY and by 24% from the previous quarter
The net margin has dropped by 68% year-on-year and by 33% since the previous quarter
Growth
What is Perspective Therapeutics's growth rate over time
Valuation
What is Perspective Therapeutics stock price valuation
P/E
N/A
P/B
0.57
P/S
108.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
85.22
Perspective Therapeutics's EPS has increased by 29% YoY and by 18% from the previous quarter
CATX's P/B is 73% below its 5-year quarterly average of 2.1 and 73% below its last 4 quarters average of 2.1
CATX's equity is down by 12% since the previous quarter
CATX's P/S is 73% below its last 4 quarters average of 396.7
The revenue has declined by 7% since the previous quarter
Efficiency
How efficient is Perspective Therapeutics business performance
CATX's ROIC has soared by 88% YoY and by 35% QoQ
Perspective Therapeutics's ROS has plunged by 63% YoY and by 56% from the previous quarter
The ROA has increased by 44% YoY but it has decreased by 2.7% from the previous quarter
The ROE has grown by 43% YoY
Dividends
What is CATX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CATX.
Financial health
How did Perspective Therapeutics financials performed over time
CATX's total liabilities has soared by 122% year-on-year but it is down by 20% since the previous quarter
The current ratio rose by 32% since the previous quarter
The debt is 99% smaller than the equity
The debt to equity has shrunk by 67% YoY
The debt has surged by 59% year-on-year but it has declined by 4.8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.